May 24, 2013
Pfizer Inc. has announced the discontinuation of a PIII clinical study of its investigational anticancer compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL). The decision was made based on the results from an interim...read more